Aesica Pharma Takes Over R&D Company R5
Following the acquisition, R5 is expected to retain its current identity and brand and will become a subsidiary of Aesica Pharmaceuticals. Aesica Pharma said that the capability and
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Making use of HighRes dual NanoCell system, which includes two AmbiStore high-speed carousels of HighRes, Rigel is expected to perform cell-based, biochemical, and high-content screening assays against a